Clinical Trial Update: Study of SGN-30 (Anti-CD30 mAb) in Patients With Primary Cutaneous Anaplastic Large Cell Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update reports results from a Phase 2 study of SGN-30 in patients with primary cutaneous anaplastic large cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Anaplastic Large Cell Lymphoma
• Large-cell Lymphoma

Drugs mentioned

• Brentuximab vedotin (Brentuximab vedotin)

Snippet

Sponsor: Seagen Inc. | Conditions: Large Cell Lymphoma | Phase 2 | Status: COMPLETED